Production (Stage)
Mineralys Therapeutics, Inc.
MLYS
$16.12
$0.503.20%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 42.53% | 78.79% | 62.19% | 53.08% | 74.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.69% | 86.81% | 128.77% | 187.05% | 136.73% |
| Operating Income | -25.69% | -86.81% | -128.77% | -187.05% | -136.73% |
| Income Before Tax | -33.97% | -100.69% | -147.55% | -237.81% | -149.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.97% | -100.69% | -147.55% | -237.81% | -149.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.97% | -100.69% | -147.55% | -237.81% | -149.90% |
| EBIT | -25.69% | -86.81% | -128.77% | -187.05% | -136.73% |
| EBITDA | -25.68% | -- | -- | -- | -- |
| EPS Basic | -13.15% | -61.06% | -98.42% | -172.10% | -37.83% |
| Normalized Basic EPS | -13.13% | -61.05% | -98.46% | -172.08% | -37.84% |
| EPS Diluted | -13.15% | -61.06% | -98.42% | -172.10% | -37.83% |
| Normalized Diluted EPS | -13.13% | -61.05% | -98.46% | -172.08% | -37.84% |
| Average Basic Shares Outstanding | 18.40% | 24.60% | 24.75% | 24.15% | 81.31% |
| Average Diluted Shares Outstanding | 18.40% | 24.60% | 24.75% | 24.15% | 81.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |